Eyenovia (NSDQ:EYEN) announced today that it appointed renowned ophthalmologist Dr. Julia Haller to its board of directors. New York-based Eyenovia adds the experienced Haller to its board as it continues to develop the MydCombi fixed-combination mydriatic agent for potential use in comprehensive eye exams with a formulation for touchless fixed-combination microdosing to improve the patient […]
Personnel Moves
Lyndra Therapeutics appoints Jenkins, Fernandes to executive roles
Lyndra Therapeutics announced today that it appointed Abigail Jenkins and Jacqueline Fernandes to executive positions at the company. Jenkins will take over as chief commercial & business officer, while Fernandes assumes the role of VP of data compliance and information technology at the Watertown, Mass.-based developer of oral, long-acting, sustained-release therapeutics. “We are pleased to […]
Dexcom promotes Jereme Sylvain to CFO
Dexcom (NASDAQ: DXCM) announced today that it has promoted Jereme Sylvain to become a new EVP and CFO at the continuous glucose monitoring company. Sylvain — who joined Dexcom in 2018 and was most recently SVP of finance and chief accounting officer — will report to COO Quentin Blackford. Previously, Blackford had been serving as […]
Injectable medicine technology developer ApiJect Systems appoints new COO
ApiJect Systems announced that Raymond J. Guidotti joined the company as its new chief operating officer. Stamford, Conn.-based ApiJect, which develops technologies for vaccines and injectable medicines to be filled, finished and delivered, made the personnel move effective on March 1, 2021, according to a news release. Guidotti is a veteran of more than 30 […]
AVEO Oncology names new chief commercial officer
AVEO Oncology (NSDQ:AVEO) announced that it appointed Mike Ferraresso as its new chief commercial officer. Boston-based AVEO Oncology said in a news release that Feraresso will manage the company’s commercial strategy and operations, including the commercialization of Fotivda (tivozanib), a differentiated, oral, once-daily, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). Fotivda is […]
Wearable infusion device maker Bexson Biomedical appoints SVP of drug delivery
Bexson Biomedical announced today that it appointed Sheldon Moberg as its new senior vice president of drug delivery. Santa Barbara, Calif.–based Bexson said in a news release that Moberg will lead the development of its drug delivery technologies, starting with a wearable infusion device for its BB106 therapy developed in partnership with Stevanato Group. The […]
Tandem Diabetes Care appoints Dr. Jordan Pinsker as its medical director
Tandem Diabetes Care (NSDQ:TNDM) announced today that it appointed Dr. Jordan Pinsker as its VP & medical director. The San Diego-based insulin delivery technology developer’s appointment of Pinsker will be made effective on April 26, 2021, according to a news release. Pinsker joins Tandem from Sansum Diabetes Research Institute in Santa Barbara, Calif., where he served […]
B. Braun Medical appoints new CFO
B. Braun Medical announced today that it appointed James Allen as a senior VP and as the company’s chief financial officer. Allen, a veteran of more than 30 years in finance and management within multiple industries and disciplines, will replace Bruce Heugel, who last year announced that he would retire after more than 20 years at […]
Re-Vana Therapeutics appoints new COO, VP of R&D
Re-Vana Therapeutics announced today that it appointed Michael Nash as chief commercial officer and David Shima as VP of R&D. Belfast, Northern Ireland-based Re-Vana’s two new executives are set to help the company develop its sustained-release therapies for ophthalmic indications, including neovascular age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and glaucoma, according to a […]
Acorda Therapeutics announces departure of business operations chief
Acorda Therapeutics (NSDQ:ACOR) announced today that its chief of business operations, David Lawrence, is resigning from the company. Lawrence, who also serves as Acorda’s principal accounting and financial officer, is resigning effective mid-March 2021 as he is set to take a leadership position at an early-stage biotechnology company, according to a news release. “Dave has […]
